AbstractIntroductionMild cognitive impairment (MCI) has clinical value in its ability to predict later dementia. A better understanding of cognitive profiles can further help delineate who is most at risk of conversion to dementia. We aimed to (1) examine to what extent the usual MCI subtyping using core criteria corresponds to empirically defined clusters of patients (latent profile analysis [LPA] of continuous neuropsychological data) and (2) compare the two methods of subtyping memory clinic participants in their prediction of conversion to dementia.MethodsMemory clinic participants (MCI, n = 139) and age-matched controls (n = 98) were recruited. Participants had a full cognitive assessment, and results were grouped (1) according to trad...
BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the pr...
Background: Despite having the same histopathological characteristics, early-onset and late-onset Al...
Abstract Background: Cerebrospinal fluid (CSF) levels assessment of A\u3b21-42 and Tau proteins may ...
AbstractIntroductionMild cognitive impairment (MCI) has clinical value in its ability to predict lat...
The amnestic form of mild cognitive impairment (aMCI) is understood to be a prodromal state of Alzhe...
Context: The likelihood of conversion to Alzheimer disease (AD) in mild cognitive impairment (MCI) a...
Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER)Altres ajuts: Generalitat de Catalunya. Pr...
Background: Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make...
BACKGROUND: Patients with amnestic mild cognitive impairment (aMCI) have an increased risk of dement...
Objective: Public health campaigns encouraging early help seeking have increased rates of mild cogni...
Rationale: Research in conventional mild cognitive impairment (MCI), a prodromal stage between ...
Objective: To identify the existence of discrete cognitive subtypes among memory clinic patients wit...
Background/Aims: To identify prodromal Alzheimer's disease (AD) subjects using a data-driven approac...
Introduction - Mild Cognitive Impairment (MCI) is widely considered to be a phase of transition betw...
Prevalence and incidence of predementia syndromes vary as a result of different diagnostic criteria,...
BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the pr...
Background: Despite having the same histopathological characteristics, early-onset and late-onset Al...
Abstract Background: Cerebrospinal fluid (CSF) levels assessment of A\u3b21-42 and Tau proteins may ...
AbstractIntroductionMild cognitive impairment (MCI) has clinical value in its ability to predict lat...
The amnestic form of mild cognitive impairment (aMCI) is understood to be a prodromal state of Alzhe...
Context: The likelihood of conversion to Alzheimer disease (AD) in mild cognitive impairment (MCI) a...
Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER)Altres ajuts: Generalitat de Catalunya. Pr...
Background: Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make...
BACKGROUND: Patients with amnestic mild cognitive impairment (aMCI) have an increased risk of dement...
Objective: Public health campaigns encouraging early help seeking have increased rates of mild cogni...
Rationale: Research in conventional mild cognitive impairment (MCI), a prodromal stage between ...
Objective: To identify the existence of discrete cognitive subtypes among memory clinic patients wit...
Background/Aims: To identify prodromal Alzheimer's disease (AD) subjects using a data-driven approac...
Introduction - Mild Cognitive Impairment (MCI) is widely considered to be a phase of transition betw...
Prevalence and incidence of predementia syndromes vary as a result of different diagnostic criteria,...
BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the pr...
Background: Despite having the same histopathological characteristics, early-onset and late-onset Al...
Abstract Background: Cerebrospinal fluid (CSF) levels assessment of A\u3b21-42 and Tau proteins may ...